Life
Pfizer's Lyme Vaccine Demonstrates Efficacy, Fails Key Statistical Benchmark
Pfizer's new Lyme disease vaccine presents promising efficacy results but has not met a crucial statistical threshold, raising questions about its deployment.
Editorial Staff
1 min read
Pfizer has developed a new vaccine targeting Lyme disease, which impacts nearly half a million Americans annually.
While the vaccine has shown some efficacy in trials, it did not meet a significant statistical hurdle necessary for broader approval.
This outcome may influence future vaccine development strategies and public health responses to Lyme disease.